Protagonist Therapeutics PTGX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $56.37M+658% | $7.44M+57.8% | $4.71M-15.0% | $5.55M-80.4% | $28.32M-83.4% | ||
| $46.74M+0.8% | $46.36M+15.9% | $40M+8.0% | $37.04M+3.2% | $35.89M+2.8% | ||
| $13.28M+16.1% | $11.43M+2.7% | $11.13M+5.5% | $10.55M-10.1% | $11.74M+31.1% | ||
| $60.02M+3.8% | $57.79M+13.0% | $51.13M+7.5% | $47.59M-0.1% | $47.63M+8.6% | ||
| -$3.65M+92.8% | -$50.36M-8.5% | -$46.42M-10.4% | -$42.04M-118% | -$19.31M-115% | ||
| -6.5%+671pp | -677.1%+308pp | -985.2%-227pp | -758%-690pp | -68.2%-142pp | ||
| $53K— | —— | $33K-8.3% | $36K-56.1% | $82K+165% | ||
| $2.28M+105% | -$43.72M-11.1% | -$39.34M-13.7% | -$34.6M-197% | -$11.66M-109% | ||
| -$1.5M-326% | $666K— | $0-100% | $172K— | $0-100% | ||
| $3.78M+109% | -$44.38M-12.8% | -$39.34M-13.1% | -$34.77M-198% | -$11.66M-109% | ||
| 6.7%+604pp | -596.8%+238pp | -834.9%-208pp | -627%-586pp | -41.2%-118pp | ||
| $0.05+107% | -$0.70-12.9% | -$0.62-12.7% | -$0.55-189% | -$0.19-109% | ||
| -$3.24M+93.5% | -$49.98M-8.5% | -$46.06M-10.4% | -$41.74M-119% | -$19.07M-115% | ||
| -5.7%+666pp | -672%+305pp | -977.5%-225pp | -752.6%-685pp | -67.3%-142pp | ||
| -$3.65M+92.8% | -$50.36M-8.5% | -$46.42M-10.4% | -$42.04M-118% | -$19.31M-115% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Protagonist Therapeutics's revenue?
- Protagonist Therapeutics (PTGX) generated $74.1M in revenue over the trailing twelve months, down 64.4% year over year.
- Is Protagonist Therapeutics profitable?
- Protagonist Therapeutics is not currently profitable: it reported a net loss of $114.7M over the trailing twelve months, a -154.9% net margin.
- What is Protagonist Therapeutics's earnings per share?
- Protagonist Therapeutics's diluted EPS over the trailing twelve months is $-1.82.
- Where does Protagonist Therapeutics's income statement data come from?
- Every line is extracted from Protagonist Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
